Safety and Efficacy of Bosutinib in Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After Resistance or Intolerance to Imatinib

CME test	Downloadable PDF	PowerPoint slides	CME Information and Faculty Disclosures
Read Dr Love's original email (from July 27, 2010)			Subscribe to Dr Love's email alerts

Slides from a presentation at ASCO 2010 and transcribed comments from a recent interview with Hagop M Kantarjian, MD (6/30/10)

 

Cortes JE et al. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). Proc ASCO 2010;Abstract 6502.

Go to previous Journal Club